https://iecure.com/wp-content/uploads/logo-fiercebiotech.svg
52
280
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2024-08-05 18:51:242024-08-05 19:01:48Introducing Fierce Biotech’s 2024 Fierce 15
https://iecure.com/wp-content/uploads/philadelphia-logo.svg
0
0
eallison
/wp-content/uploads/iEcure_logo.png
eallison2024-05-29 17:19:002024-05-29 17:46:01University of Pennsylvania gene-editing spinout iEcure hits the FDA trifecta
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2024-05-07 05:00:362024-05-07 08:06:38iECURE Receives FDA Fast Track Designation for ECUR-506 for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
https://iecure.com/wp-content/uploads/endpoint-news.svg
52
280
eallison
/wp-content/uploads/iEcure_logo.png
eallison2024-04-12 15:36:162024-04-12 15:49:23Exclusive: Jim Wilson startup gets FDA green light for first test of gene editing in babies
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2024-04-04 08:00:252024-04-04 08:03:08iECURE Announces FDA Clearance of Investigational New Drug Application for ECUR-506 to Initiate OTC-HOPE Trial for Treatment of Neonatal Onset Ornithine Transcarbamylase Deficiency in the U.S.
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2024-03-05 19:31:452024-03-05 19:33:00iECURE Secures Approval from U.K. Medicines & Healthcare Products Regulatory Agency to Expand the OTC-HOPE Study of ECUR-506
/wp-content/uploads/iEcure_logo.png
0
0
eallison
/wp-content/uploads/iEcure_logo.png
eallison2023-12-12 18:17:352023-12-13 08:07:51iECURE Secures Clearance from Australian Therapeutic Goods Administration for its Clinical Trial Approval for the OTC-HOPE Phase 1/2 Study of ECUR-506
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2023-03-21 18:54:482023-03-24 17:25:20European Commission Grants Orphan Designation for iECURE’s Lead Product Candidate GTP-506 for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2023-03-15 19:15:252023-03-23 14:57:07iECURE Appoints Gabriel M. Cohn, M.D., as Chief Medical Officer
/wp-content/uploads/iEcure_logo.png
0
0
David Anderson
/wp-content/uploads/iEcure_logo.png
David Anderson2022-11-30 00:00:412023-03-24 17:26:58iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases
Scroll to top
